Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
14α-lanosterol demethylase (CYP51A1) is a cytochrome P450 enzyme that catalyzes the oxidative removal of the 14α-methyl group from lanosterol, an essential step in the conversion of lanosterol to cholesterol in animals and ergosterol in fungi. It is a key target for azole antifungal drugs, which inhibit ergosterol synthesis in fungi.
Inhibition of ergosterol synthesis by binding to the heme iron in the active site.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 14α-lanosterol demethylase.